Metastatix, Inc. Closes $35 Million Series B Financing
Published: Oct 09, 2007
Metastatix, an emerging pharmaceutical company focused on the development of small molecule therapeutics, announced today it has secured $35 million in Series B financing. The new round of funding primarily will be used to conduct clinical trials of the company's lead candidate, MSX-122, in cancer patients and to advance the company's development programs in inflammation and HIV infection.